Answers are grounded in this paper and cite their sources.
Experimental study demonstrates tumor growth inhibition via survivin mutant expression in melanoma models, highlighting antiapoptotic pathways as viable therapeutic targets.
A role of apoptosis (programmed cell death) in tumor formation and growth was investigated by targeting the apoptosis inhibitor survivin in vivo. Expression of a phosphorylation-defective survivin mutant (Thr(34)-->Ala) triggered apoptosis in several human melanoma cell lines and enhanced cell death induced by the chemotherapeutic drug cisplatin in vitro. Conditional expression of survivin Thr(34)-->Ala in YUSAC2 melanoma cells prevented tumor formation upon s.c. injection into CB.17 severe combined immunodeficient-beige mice. When induced in established melanoma tumors, survivin Thr(34)-->Ala inhibited tumor growth by 60-70% and caused increased apoptosis and reduced proliferation of melanoma cells in vivo. Manipulation of the antiapoptotic pathway maintained by survivin may be beneficial for cancer therapy.
No takes yet. Share an insight, caveat, or question.
Grossman et al. (2001) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: